EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

Janet Weber, Marcus Schley, Matthias Casutt, Helmut Gerber, Guido Schuepfer, Roman Rukwied, Wolfgang Schleinzer, Michael Ueberall, Christoph Konrad

Anesthesiology Research and Practice · 2009

DOI: 10.1155/2009/827290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anesthesiology Research and Practice, 2009. Verfasst von Janet Weber und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Kantonsspital Lucerne, 6000 Lucerne, Switzerland. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Bionorica.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central neuropathic pain is difficult to treat, but delta 9-Tetrahydrocannabinol (delta 9-THC) may be a promising therapeutic agent. We administered in 172 patients on average 7.5 mg delta 9-THC over 7 months. Of these, 48 patients prematurely withdrew due to side effects, insufficient analgesia, or expense of therapy. Thus, 124 patients were assessed retrospectively in a multicenter telephone survey. Reported changes in pain intensity, recorded on a numeric rating scale (NRS), Pain Disability Index (PDI), Medical Outcomes Short-Form (SF-12), Quality of Life Impairment by Pain (QLIP), Hospital Anxiety Depression Scale (HADS), and amount of concomitant pain medication were recorded. Psychometric parameters (PDI, SF-12, QLIP, HADS) and pain intensity improved significantly during delta 9-THC treatment. Opioid doses were reduced and patients perceived THC therapy as effective with tolerable side effects. About 25% of the patients, however, did not tolerate the treatment. Therapy success and tolerance can be assessed by a transient delta 9-THC titration and its maintained administration for several weeks. The present survey demonstrates its ameliorating potential for the treatment of chronic pain in central neuropathy and fibromyalgia. A supplemental delta 9-THC treatment as part of a broader pain management plan therefore may represent a promising coanalgesic therapeutic option.

Autor:innen und Institutionen

  • Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Kantonsspital Lucerne, 6000 Lucerne, Switzerland.

Förderung

  • Bionorica

Zitieren

APA

Weber, J., Schley, M., Casutt, M., Gerber, H., Schuepfer, G., Rukwied, R., Schleinzer, W., Ueberall, M., & Konrad, C. (2009). Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. Anesthesiology Research and Practice. https://doi.org/10.1155/2009/827290

Vancouver

Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. Anesthesiology Research and Practice. 2009. doi:10.1155/2009/827290

BibTeX
@article{Weber2009,
  author = {Weber, Janet and Schley, Marcus and Casutt, Matthias and Gerber, Helmut and Schuepfer, Guido and Rukwied, Roman and Schleinzer, Wolfgang and Ueberall, Michael and Konrad, Christoph},
  title = {Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey},
  journal = {Anesthesiology Research and Practice},
  year = {2009},
  doi = {10.1155/2009/827290}
}
Kostenlos starten →